Insider Selling: Alkermes PLC (NASDAQ:ALKS) Director Sells 1,500 Shares of Stock

Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $54.91, for a total transaction of $82,365.00. Following the sale, the director now directly owns 9,500 shares in the company, valued at approximately $521,645. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Alkermes PLC (NASDAQ ALKS) traded down 0.04% during mid-day trading on Friday, reaching $50.90. 701,043 shares of the company traded hands. Alkermes PLC has a 52-week low of $41.93 and a 52-week high of $63.40. The firm’s 50 day moving average price is $55.78 and its 200-day moving average price is $57.15. The company’s market capitalization is $7.82 billion.

Alkermes PLC (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.02. The firm had revenue of $218.80 million during the quarter, compared to analysts’ expectations of $216.54 million. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. Alkermes PLC’s quarterly revenue was up 12.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.01) EPS. Equities analysts predict that Alkermes PLC will post ($0.04) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Alkermes PLC (NASDAQ:ALKS) Director Sells 1,500 Shares of Stock” was reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/alkermes-plc-nasdaqalks-director-sells-82365-00-in-stock-updated-updated.html.

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of Alkermes PLC by 5,927.5% in the first quarter. BlackRock Inc. now owns 10,292,601 shares of the company’s stock worth $602,115,000 after buying an additional 10,121,839 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Alkermes PLC by 13,784.0% in the second quarter. Janus Henderson Group PLC now owns 2,330,992 shares of the company’s stock worth $135,128,000 after buying an additional 2,314,203 shares during the last quarter. Primecap Management Co. CA raised its position in shares of Alkermes PLC by 23.2% in the first quarter. Primecap Management Co. CA now owns 7,856,543 shares of the company’s stock worth $459,608,000 after buying an additional 1,480,273 shares during the last quarter. Janus Capital Management LLC raised its position in shares of Alkermes PLC by 220.0% in the first quarter. Janus Capital Management LLC now owns 1,658,928 shares of the company’s stock worth $97,045,000 after buying an additional 1,140,555 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Alkermes PLC by 40.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,857,077 shares of the company’s stock worth $167,138,000 after buying an additional 820,355 shares during the last quarter. 97.19% of the stock is currently owned by institutional investors.

Several analysts have recently issued reports on ALKS shares. Cowen and Company reissued a “buy” rating on shares of Alkermes PLC in a research report on Friday, April 28th. ValuEngine cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Credit Suisse Group set a $70.00 price target on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, May 19th. Finally, BidaskClub cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $63.00.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply